Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Stopped early · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma

In brief

Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.

Key facts

Study ID

NCT00120198

Run by

Geriatric Oncology Consortium

People needed

50

Starts

2005-03-01

Expected to finish

2006-09-01

Last updated by the study team

2007-11-16

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 65 years and older;
• Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;
• Previously untreated;
• ECOG 0-2
• Adequate renal and hepatic functions;
• Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG;
• Signed informed consent

You may not qualify if…

• CNS involvement by lymphoma;
• Hypersensitivity to study drugs;
• Active infection;
• Prior treatment with monoclonal antibodies for cancer;
• History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure

Where it is running

• Study site — Oxnard, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Inverness, Florida, United States
• Study site — Lecanto, Florida, United States
• Study site — Belleville, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.